Provided by Tiger Trade Technology Pte. Ltd.

HENLIUS

64.800
+0.1000.15%
Volume:558.92K
Turnover:35.48M
Market Cap:35.22B
PE:38.91
High:64.900
Open:64.900
Low:62.050
Close:64.700
52wk High:92.000
52wk Low:15.200
Shares:543.49M
HK Float Shares:163.43M
Volume Ratio:0.90
T/O Rate:0.34%
Dividend:- -
Dividend Rate:- -
EPS(LYR):1.665
ROE:27.54%
ROA:4.97%
PB:9.37
PE(LYR):38.91
PS:5.51

Loading ...

Shanghai Henlius Biotech H1 Revenue RMB 2,819.5 Million

THOMSON REUTERS
·
Aug 25

HENLIUS (02696): International Multicenter Phase 2 Clinical Study of Injectable HLX43 (PD-L1 Targeted Antibody-Drug Conjugate) for Advanced Non-Small Cell Lung Cancer Completes First Patient Dosing in the United States

Stock News
·
Aug 22

Hong Kong Stocks Movement | HENLIUS (02696) Surges Over 8% to New Highs in Afternoon Trading Following Introduction of Qingde's Phase III Innovative HER2 ADC

Stock News
·
Aug 21

BRIEF-UBS Group AG's Long Position In H-Shares Of Shanghai Henlius Biotech Decreases To 3.53% On August 13 From 5.91% - HKEX

Reuters
·
Aug 18

Hong Kong Stocks Movement | HENLIUS (02696) Surges Over 5% to New High as Three Core Products Feature at WCLC, Citi Highlights HLX43 Latest Data

Stock News
·
Aug 14

BRIEF-Shanghai Henlius Biotech Says New Drug Application For Recombinant Anti-VEGF-Humanised Monoclonal Antibody Injection HLX04-O Accepted By NMPA

Reuters
·
Aug 13

Henlius Biotech Gets China Acceptance for Macular Degeneration Drug Application

MT Newswires Live
·
Aug 13

Shanghai Henlius Biotech - New Drug Application for Recombinant Anti-Vegf-Humanised Monoclonal Antibody Injection Hlx04-O Accepted by Nmpa

THOMSON REUTERS
·
Aug 13

BRIEF-Shanghai Henlius Biotech Says FDA Approves HLX43 For Phase 1 Clinical Trial For Treatment Of Thymic Carcinoma

Reuters
·
Aug 07

Shanghai Henlius Biotech - FDA Approves Hlx43 for Phase 1 Clinical Trial for Treatment of Thymic Carcinoma

THOMSON REUTERS
·
Aug 07

Henlius Biotech Doses First Patient in Glomerulonephritis Drug Trial

MT Newswires Live
·
Aug 06

Henlius Ships First Batch of Serplulimab to India, Expanding Global Access to Innovative Cancer Treatment

Reuters
·
Aug 01

Shanghai Henlius Biotech Inc. Announces Upcoming Board Meeting to Approve Interim Results and Dividend

Reuters
·
Aug 01

Henlius Wins EMA Panel Backing for Denosumab Biosimilar HLX14; Shares Gain 4%

MT Newswires Live
·
Jul 29

Shanghai Henlius Biotech Inc. Receives Positive Opinion from EMA for Denosumab Biosimilar HLX14, Regulatory Reviews Ongoing in US and Canada

Reuters
·
Jul 28

Shanghai Henlius Biotech Inc. Conducted Extraordinary General Meeting

Reuters
·
Jul 21

Henlius (02696) Surges 5% Again on HLX22 US Trial Milestone and HLX43 Global Approvals

Market Watcher
·
Jul 16

Henlius Biotech (02696) Surges Nearly 6% Again as HLX22 Phase 3 Trial Doses First US Patient; HLX43 Gains Multi-Nation Clinical Approval

Stock Track
·
Jul 16

HENLIUS Gains Nearly 5% as First US Patient Dosed in HLX22 Phase 3 Trial

Market Watcher
·
Jul 16

Henlius Biotech (02696) Surges Over 4% as HLX22 Phase 3 Trial Administers First US Patient Dose

Market Watcher
·
Jul 15